title: A pilot psychometric study of aberrant salience state in patients with Parkinson's disease and its association with dopamine replacement therapy.
abstract: An overactive striatal dopaminergic neurotransmission is described in psychosis and may be associated with a state of aberrant salience attribution. This pilot psychometric study investigated if features suggestive of an aberrant salience state, a condition of psychosis proneness, are associated with dopamine replacement therapy in patients with early Parkinson's disease (PD). 77 participants (50 medicated PD patients, 12 newly diagnosed drug-naive PD patients and 15 healthy controls) were enrolled and assessed with the Aberrant Salience Inventory (ASI). Differences between groups were found for ASI scores, and ASI scores correlated with the dopaminergic therapy, in particular levodopa. These findings preliminary suggested that the presence and the degree of an aberrant salience state may be associated with features of the dopaminergic therapy; further studies are needed to investigate which neuropsychiatric complications more common in PD patients may be characterized by an underlying aberrant salience state.
authors.affiliation: Department of Mental Health and Pathological Addiction, AUSL of Reggio Emilia, Reggio Emilia, Italy, michelepoletti79@gmail.com.
authors.forename: Michele
authors.initials: M
authors.lastname: Poletti
authors.forename: Daniela
authors.initials: D
authors.lastname: Frosini
authors.forename: Cristina
authors.initials: C
authors.lastname: Pagni
authors.forename: Filippo
authors.initials: F
authors.lastname: Baldacci
authors.forename: Claudio
authors.initials: C
authors.lastname: Lucetti
authors.forename: Paolo
authors.initials: P
authors.lastname: Del Dotto
authors.forename: Roberto
authors.initials: R
authors.lastname: Ceravolo
authors.forename: Ubaldo
authors.initials: U
authors.lastname: Bonuccelli
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001288:Attention / Q000187:drug effects*; D015259:Dopamine Agents / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D010865:Pilot Projects; D011594:Psychometrics; D011605:Psychoses, Substance-Induced
chemical_list: D000978:Antiparkinson Agents; D015259:Dopamine Agents